Concentra Group Holdings Parent, Inc. reported robust second quarter results for the period ended June 30, 2026, posting revenue growth of 10.0%, net income growth of 45.7%, and Adjusted EBITDA growth of 22.5% compared to the same quarter of the prior year. The company also raised its full-year 2026 financial guidance and announced a planned leadership transition effective November 1, 2026.

Second Quarter 2026 Financial Highlights

The following table summarizes key financial metrics for the three months ended June 30, 2026 compared to the three months ended June 30, 2025:

For the six months ended June 30, 2026, revenue totaled $1,175.6 million, up 11.8% from $1,051.5 million in the same period of the prior year. Net income attributable to the Company for the six-month period grew 38.7% to $115.8 million, with basic and diluted earnings per share of $0.90 compared to $0.65 in the prior year period.

Balance Sheet and Cash Flow

As of June 30, 2026, Concentra's balance sheet reflected cash of $158.0 million, total debt of $1,573.6 million, and total assets of $3,010.3 million. The net leverage ratio of 2.99x was in compliance with the financial covenant under the company's credit agreement.

Cash flows provided by operating activities in Q2 2026 totaled $135.2 million, compared to $88.4 million in Q2 2025. The increase was primarily attributed to higher net income from organic growth, acquisitions, and de novos, as well as year-over-year variances in the timing of current liability payments. Free Cash Flow for the quarter was $121.0 million, compared to $63.2 million in Q2 2025. Cash flow from financing activities used $24.7 million during the quarter, driven primarily by $11.0 million in share repurchases and $8.0 million in dividend payments, resulting in a net increase in cash of $96.3 million for the quarter.

During Q2 2026, the company repurchased approximately 0.4 million shares of common stock totaling $11.0 million.

Operational Metrics and Network

The following table presents key facility and operational statistics as of the end of Q2 2026 versus Q2 2025:

Concentra supports the care of approximately 54,000 patients each business day on average across 46 states and the District of Columbia, served through its 633 occupational health centers, 415 onsite health clinics at employer worksites, and Concentra Telemed as of June 30, 2026. The company employs approximately 13,000 colleagues and affiliated physicians and clinicians.

Dividend Declaration

On August 5, 2026, the board of directors declared a cash dividend of $0.0625 per share, payable on or about August 28, 2026, to stockholders of record as of the close of business on August 20, 2026. The declaration and payment of future dividends remain at the discretion of the board after taking into account the company's financial condition, operating results, available cash, terms of indebtedness, and other relevant factors.

Raised Full-Year 2026 Guidance

Concentra raised its financial guidance for the full year 2026. The updated outlook is as follows:

Leadership Transition

As part of a multiyear succession process unanimously approved by the board of directors, effective November 1, 2026, Matt DiCanio — currently president and chief financial officer — will become president and chief executive officer and serve as a Class III director on the board. Keith Newton will transition from chief executive officer and director to executive chairman of the board. Additionally, Robert Ortenzio has notified the board of his intent to resign from the role of chairman of the board while continuing to serve as a director, effective November 1, 2026.

DiCanio has served as president since 2023 and chief financial officer since 2024. During his 11-year tenure, his responsibilities have spanned clinical functions, operations, sales, marketing, corporate strategy, finance, and business development. He has led multiple business units and major acquisition integrations and played an integral role in Concentra's transition to a publicly traded company. The company expects to announce its chief financial officer succession plan prior to the leadership transition taking effect on November 1, 2026.

Concentra Group Holdings Inc. raised its fiscal year 2026 sales guidance to a range of $2.325 billion to $2.375 billion, signaling robust demand for its integrated healthcare services. The revised outlook surpasses the consensus market estimate of $2.334 billion, indicating that the company expects to deliver top-line performance above analyst expectations for the period.

The update reflects management’s confidence in the company’s ability to capture additional revenue opportunities across its network. By raising the lower bound of its guidance from $2.275 billion to $2.325 billion, Concentra has effectively narrowed the range while lifting the floor significantly above prior projections.

Guidance Update Details

The following table outlines the changes in the sales outlook:

The upper end of the guidance remains unchanged at $2.375 billion, suggesting that the primary adjustment relates to the minimum expected revenue rather than a ceiling expansion.

What the Numbers Show

The revised lower bound of $2.325 billion now sits just below the market estimate of $2.334 billion, implying that even the conservative scenario anticipates near-consensus performance. This shift reduces downside risk for investors and suggests that operational momentum is strong enough to support higher revenue floors without altering the maximum potential upside.